Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ORE PHARMACEUTICAL HOLDINGS INC. (ORXE)
|
Add to portfolio |
|
|
|
| Price: |
$0.19
| | Metrics |
| OS: |
5.47
|
M
| |
-245
|
% ROE
|
| Market cap: |
$1.06
|
M
| |
|
|
|
Net cash:
|
$2.78
|
M
| |
$0.51
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($5.7)
|
M
| |
|
|
|
EBIT
|
($5.7)
|
M
| |
|
|
| EPS |
($0.49)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Sep-30-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 |
| Revenues | 0.2 | 2.0 | 11.9 | 8.4 | 24.3 | 6.6 | 52.2 | 69.5 |
| Revenue growth | -91.0% | -83.6% | 41.1% | 28.3% | | -87.4% | -25.0% | 26.7% |
| Cost of goods sold | 2.5 | 9.8 | 10.3 | 8.4 | 42.5 | 6.6 | 44.3 | 67.6 |
| Gross profit | -2.3 | -7.9 | 1.6 | 0.0 | -18.2 | 0.0 | 7.9 | 2.0 |
| Gross margin | -1310.9% | -403.7% | 13.5% | 0.0% | -74.7% | 0.0% | 15.1% | 2.8% |
| Selling, general and administrative | 7.2 | 12.7 | 11.1 | 12.2 | 22.4 | 13.2 | 19.2 | 22.2 |
| Research and development | | | | | | | | |
| EBIT | -8.9 | -23.5 | -19.8 | -20.5 | -40.6 | -19.1 | -11.4 | -20.2 |
| EBIT margin | -5082.9% | -1206.3% | -166.7% | -244.4% | -166.8% | -291.9% | -21.8% | -29.1% |
| Pre-tax income | -8.4 | -22.5 | -17.8 | -18.1 | -38.3 | -17.2 | -18.8 | -22.5 |
| Income taxes | 0.0 | 0.0 | 16.9 | 36.6 | 0.0 | 31.1 | 0.3 | 2.2 |
| Tax rate | 0.0% | 0.0% | | | 0.0% | | | |
| Net income | -8.4 | -22.5 | -34.7 | -54.7 | -54.7 | -48.3 | -28.5 | -24.8 |
| Net margin | -4790.3% | -1151.8% | -292.6% | -651.1% | -224.7% | -737.2% | -54.7% | -35.6% |
| |
| Diluted EPS | ($1.53) | ($3.97) | ($5.44) | ($1.72) | ($1.20) | ($1.52) | ($0.61) | ($0.82) |
| Shares outstanding (diluted) | 5.5 | 5.7 | 6.4 | 31.8 | 31.8 | 31.7 | 31.5 | 30.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|